Caribou Biosciences, Inc. (CRBU)
NASDAQ: CRBU · Real-Time Price · USD
1.430
+0.120 (9.16%)
At close: Jan 31, 2025, 4:00 PM
1.460
+0.030 (2.10%)
After-hours: Jan 31, 2025, 7:01 PM EST
Caribou Biosciences Revenue
Caribou Biosciences had revenue of $2.02M in the quarter ending September 30, 2024, a decrease of -91.45%. This brings the company's revenue in the last twelve months to $11.48M, down -66.85% year-over-year. In the year 2023, Caribou Biosciences had annual revenue of $34.48M with 148.91% growth.
Revenue (ttm)
$11.48M
Revenue Growth
-66.85%
P/S Ratio
11.18
Revenue / Employee
$72,627
Employees
158
Market Cap
129.49M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 34.48M | 20.63M | 148.91% |
Dec 31, 2022 | 13.85M | 4.25M | 44.31% |
Dec 31, 2021 | 9.60M | -2.76M | -22.35% |
Dec 31, 2020 | 12.36M | 6.57M | 113.56% |
Dec 31, 2019 | 5.79M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 63.17B |
AbbVie | 56.33B |
Novartis AG | 51.72B |
AstraZeneca | 51.21B |
Thermo Fisher Scientific | 42.88B |
Abbott Laboratories | 41.95B |
CRBU News
- 3 days ago - DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Caribou Biosciences - GlobeNewsWire
- 8 days ago - SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Caribou Biosciences - Accesswire
- 12 days ago - Caribou Biosciences, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm for More Information - CRBU - PRNewsWire
- 19 days ago - Shareholders of Caribou Biosciences, Inc. Should Contact The Gross Law Firm Before February 24, 2025 to Discuss Your Rights - CRBU - PRNewsWire
- 19 days ago - Caribou Biosciences Initiates the CB-010 GALLOP Phase 1 Trial in Lupus and Provides Outlook for Multiple Clinical Datasets in 2025 - GlobeNewsWire
- 24 days ago - INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Caribou Biosciences - Accesswire
- 24 days ago - Caribou Biosciences to Present at 43rd Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 25 days ago - The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of February 24, 2025 in Caribou Biosciences, Inc. Lawsuit – CRBU - GlobeNewsWire